  Voriconazole is a broad-spectrum antifungal agent and is mainly metabolized by the liver , yet there have been no reports about voriconazole treatment in patients with Child-Pugh class C cirrhosis. The objective of this study was to investigate the pharmacokinetic profile and safety of voriconazole treatment in this cohort of patients. A retrospective , multicenter study was performed in patients with Child-Pugh class C cirrhosis who received a voriconazole maintenance dose of 100 mg twice daily ( group A) or 200 mg daily ( group B) orally or intravenously. All voriconazole C A total of 51 voriconazole C The voriconazole maintenance dose of 100 mg twice daily or 200 mg daily orally or intravenously may be inappropriate in patients with Child-Pugh class C cirrhosis because of the higher voriconazole C